Introduction
During the past six decades, the rate of success in curing childhood acute lymphoblastic leukemia (ALL) has increased from less than 10% to more than 80%. This dramatic improvement is largely due to optimization of the use of existing chemotherapeutic agents.
Methotrexate (MTX) is the major anti-metabolite ( Fig. 1 ) employed in combination chemotherapeutic regimens for childhood ALL. Treatment failure is mainly related to acquired drug resistance or selection of pre-existing molecular alterations facilitating antifolate resistance.
The mechanisms of action and resistance to MTX and its major metabolite 7-hydroxymethotrexate (7-OHMTX) have been characterized in some detail [1, 2] . Decreased cellular uptake via the reduced folate carrier (RFC/SLC19A1) [3] or increased active efflux mediated by ABC transporters such as the multidrug resistance-associated proteins 1-5 (MRP 1-5), the breast cancer resistance protein (BCRP/ABCG2) [4, 5] and P-glycoprotein (MDR or ABCB1) [6] can lead to resistance to hydrophilic and lipophilic antifolates. The ability of cells to accumulate long chain MTX polyglutamates (MTX-PGs) is highly dependent on the activities of folylpolyglutamate synthetase (FPGS) and folylpolyglutamate hydrolase (FPGH). Furthermore, the susceptibility of cells to the cytotoxic effect elicited by MTX may also be influenced by mutations in the dihydrofolate reductase gene (DHFR) that result in a lower affinity for MTX, by increased activity of thymidylate synthase (TS), as well as by altered activities of other folate-and one-carbon metabolism enzymes.
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A c c e p t e d M a n u s c r i p t 4 The metabolite 7-OHMTX ( Fig. 1 ) results from oxidation of MTX primarily by hepatic aldehyde oxidase. Intracellular conversion of MTX to 7-OHMTX has also been demonstrated in leukemia cells [7] . Although the affinity of DHFR for 7-OHMTX is markedly lower (>100-fold) than for MTX [8] , the polyglutamated forms of this metabolite are more potent inhibitors of this enzyme [9, 10] . Polyglutamated forms of MTX and polyglutamated conjugates of 7-OHMTX are also capable of inhibiting a number of other folate-dependent enzymes involved in de novo purine biosynthesis such as TS, glycinamide ribonucleotide formyltransferase (GARFT) and aminoimidazole carboxamide ribonucleotide formyltransferase (AICART).
We have recently reported that prolonged exposure of human leukemic T-cells to 7-OHMTX leads to antifolate resistance that attenuates the efficacy of MTX [11] . While the primary mechanism of resistance to MTX was a marked reduction in RFC-mediated drug uptake, resistance to 7-OHMTX was due to a dramatic decrease (>98%) in FPGS activity, which enhanced resistance to short-term (4 hr) exposure to MTX more than 100-fold. To further characterize the molecular mechanisms associated with acquired resistance to MTX and 7-OHMTX in human leukemia cells, we characterized gene expression profiles and alterations in gene copy numbers using high density microarrays. The results revealed disparate cellular responses to MTX and 7-OHMTX that may facilitate the identification of novel cellular targets and modalities of resistance to 7-OHMTX as well as possibly suggesting novel approaches to overcome antifolate resistance and design individualized antifolate-based drug therapy of human leukemia.
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Materials and Methods

Materials
The HG-U133A GeneChip oligonucleotide microarray and all reagents required for microarray analysis were purchased from Affymetrix (Affymetrix Inc., Santa Clara, CA, USA Plasma levels of MTX and 7-OHMTX previously determined in 49 childhood ALL patients by HPLC [12] . The conditions for sample collections and procedures and HPLC assay applied are according to previously published information [13] . In short, plasma samples were obtained after intravenous infusion of MTX (5-8 g/m 2 ) during 24 hours. Blood samples were collected 20-23 h after beginning of MTX infusion (steady-state concentration), at 36 h and once every 6 hours afterward until plasma-MTX concentration fell below <0.2 M. Samples were generally drawn from a central venous catheter, while the steady-state samples were obtained from a peripheral vein.
2.3
Antifolate-resistant cells and tissue culturing MOLT-4 cells derived from a human T-cell ALL were purchased from American Type Culture Collection (Rockville, MD, USA). The generation and functional characterization of drug resistant derivatives have been previously reported [11] . In short, this involved sequential exposure (12-18 steps each of 4 days) of parental MOLT-4 cells to gradually increasing concentrations of MTX (1-300 nM) or 7-OHMTX (50-30,000 nM). This resulted in sub-lines with greater than 50-fold increased resistance to MTX or 7-OHMTX relative to parental cells. Cells were cultured in RPMI-1640 medium (supplemented with 10% fetal calf serum, 100 U/ml penicillin, 100 µg/ml streptomycin, and 2 mM L-glutamine) at 37 C under Page 6 of 30 A c c e p t e d M a n u s c r i p t 6 a humidified air containing 5% CO 2 . For experimental studies cells were cultured in drugfree-medium for at least 3 passages, and harvested during the logarithmic phase growth at a density 0.8-1.5x10 6 /ml as determined by cell counting using a Coulter Multi-sizer (Coulter Electronics, Luton, United Kingdom).
2 . 4 I s o l a t i o n a n d Q u a l i t y V e r i f i c a t i o n o f R N A (Fig. 3) . All microarray data were submitted to http://www.ncbi.nlm.nih.gov/geo/.
Quantitative Real-time PCR (qRT-PCR)
qRT 
Array-based Comparative Genomic Hybridization (array-CGH)
Genomic DNA was extracted from cultured cells using a commercial kit (Gen Elute, Sigma) and used for analyses of gene copy number alterations by array-CGH. The experimental procedures and data analyses were according to previously published information [14] . The tiling 33k or 38k BAC arrays used were produced at the SCIBLU Genomics Centre at Lund University, Sweden (www.lu.se/sciblu). Microarray slides were hybridized for 72 h at 37 o C with differentially labeled test and reference DNA (Cy5-dCTP and Cy3-dCTP) in the presence of Cot-1 DNA, washed under stringent conditions, and nitrogen blow-dried.
Arrays were subsequently scanned using a GenePix 4200A (Axon instruments Inc., Union City, CA), and images were quantified with GenePix Pro 6.0 (Axon instruments, Wheatherford TX, USA) and uploaded in BioArray Software Environment, BASE (http://www.base.thep.lu.se/) [15] . The pin-based LOWESS algorithm [16] was used for data normalization. Relative copy numbers were determined from normalized log 2 ratios, and altered regions were defined by CGH plotter [17] 
Results
As shown in Figure 2 , as high as 30-40 M concentrations of 7-OHMTX, the primary catabolite of MTX, are readily attainable in the serum of childhood ALL patients treated with high-dose MTX [12] . Furthermore, while the parental drug MTX is efficiently cleared from the serum, relatively high levels (several M) of the catabolite 7-OHMTX that exceed those of the parent drug by ~10-fold, persist for a long time in the serum.
Accordingly, we explored the pattern of gene expression by leukemic cells that had acquired resistance to MTX or 7-OHMTX. Wild type MOLT-4 cells and their sublines selected for resistance to MTX or 7-OHMTX were characterized regarding gene expression profiles ( Fig. 3 ; Table 1 ) and DNA copy number alterations ( Table 2) . Gene expression levels were compared to gene copy numbers ( Table 3) and verified for selected genes by qRT-PCR ( Table 4) .
Expression Profiles of 7-OHMTX and MTX-Resistant cells
Nine separate hybridizations were performed on the Human Genome U133A GeneChip representing triplicate inoculates of parental, 7-OHMTX-as well as MTX-resistant MOLT-4 cells. In total, 863 probe sets showed 2-fold or more difference in expression levels between the three lines analysed (Fig. 3) . Analysis of the gene expression patterns revealed 176 genes in MTX-resistant cells and 365 genes in 7-OHMTX-resistant cells, the expression of which was more than 2-fold different from that in parental cells (p<0.05) (Fig. 3) . Forty-eight of these genes were common to both drug-resistant cell lines. Functional classification revealed frequent dysregulation of genes encoding signalling proteins in both resistant derivatives studied ( Table 1 ). In the MTX-resistant subline, the expression of genes encoding proteins A c c e p t e d M a n u s c r i p t 10 involved in DNA/RNA metabolism and membrane transport proteins were altered more profoundly, whereas in the 7-OHMTX-resistant cells, the most pronounced alterations were in transcripts coding for proteins involved in metabolism and cell proliferation ( Table 1) .
The expression levels of certain genes with functions related to folate metabolism, purine biosynthetic pathway and transport of related substances are detailed in Table 3 
Corroboration of Array Expression Levels by qRT-PCR
Analysis of the gene expression patterns of parental and resistant cells employing the Affymetrix HG-U133A microarray revealed consistent differences with respect to 9 genes, some of which encode proteins involved in folate metabolism or purine biosynthesis. These differences were confirmed by qRT-PCR ( Table 4 Table 2 ). The genomic regions of acquired gains and losses do not include the genes whose products are known to be significant in response to MTX ( Table 3 ). These findings suggest that drug-induced changes in gene expression do not stem from copy number alterations, but may instead be due to transcriptional regulatory alterations. Furthermore, gene amplifications were not detected, thereby demonstrating that increases in copy numbers of drug-resistance mediating genes were neither induced by treatment with MTX nor with exposure to 7-OHMTX.
Expression of the RFC/SLC19A1 gene was down-regulated more than 2-fold in the MTXresistant cells, thereby confirming the role of this influx transporter as an important determinant of antifolate resistance [18] [19] [20] [21] . However, the major finding of the present investigation is that the dramatic loss of FPGS activity in the 7-OHMTX cells, presumably associated with decreased intracellular levels of folate, was accompanied by consistent alterations in the expression of genes capable of preserving intracellular pools of reduced folate and/or increase purine nucleotide biosynthesis. Thus, among the major differences observed between these cell lines were the following ( Members of the family of multidrug resistance proteins, notably MRP1-5/ABCC1-5, and BCRP/ABCG2 are known to export the folate antagonist MTX out of cells [25] [26] [27] [28] [29] . Levels of BCRP and MRP1-5 mRNAs were all slightly elevated (about 50%) in the MTX-resistant subline, but unchanged in 7-OHMTX cells ( Table 3 ).
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A c c e p t e d M a n u s c r i p t 16 Cells resistant to 7-OHMTX displayed a dramatic up-regulation of VAMP8 (>700-fold) ; VAMP8 is a vesicle-associated membrane protein involved in exocytosis, and it is hence tempting to speculate here that elimination of vesicle-sequestered 7-OHMTX could be facilitated by VAMP8 overexpression. This finding warrants further studies to explore this interesting possibility.
Among the genes that encode proteins involved in the folate pathway, the expression of MTHFR was most profoundly altered in both of our antifolate-resistant cell lines (>4-fold upregulation) (Fig. 4) . A c c e p t e d M a n u s c r i p t ATP-binding cassette, sub-family C (CFTR/MRP) member 5 1.6 1.2 3q27.1 n.a n.a n.a MTHFD1 methylenetetrahydrofolate dehydrogenase 1 1.4 1.5 14q23.2 n.a n.a n.a MTHFD2 methylenetetrahydrofolate dehydrogenase 2 1.2 1.8 2p13.1 n.a n.a n.a DHFR dihydrofolate reductase 1.4 1.0 18q11.2 n.a n.a n.a TS / TYMS thymidylate synthetase 0.6 0.7 18p11.32 n.a n.a n.a MTRR 5-methyltetrahydrofolate-homocysteine methyltransferase reductase 1.1 0.9 5p15.31 n.a n.a n.a MTHFS 5,10-methenyltetrahydrofolate synthetase 1.0 0.9 15q25.1 n.a n.a n.a GCH1 GTP cyclohydrolase 1 (dopa-responsive dystonia) 1.4 0.9 14q22.2 n.a n.a n.a SLC19A2 solute carrier family 19 (thiamine transporter) member 2 1.4 2.1 1q24.2 loss loss n.a SHMT1 serine hydroxymethyltransferase 1 1.1 2.0 17p11.2 n.a n.a n.a BCRP / ABCG2 ATP-binding cassette, sub-family G (WHITE) member 2 1.7 0.4 4q22.1 n.a n.a n.a PFAS phosphoribosylformylglycinamidine synthase (FGAR amidotransferase) 1.9 2.5 17p13.1 n.a gain n.a GCHFR GTP cyclohydrolase I feedback regulator 0.6 7.7 15q15.1 n.a n.a n.a ITPA inosine triphosphatase (nucleoside triphosphate pyrophosphatase) 0.6 0.9 20p13 gain gain gain dGK/ DGUOK deoxyguanosine kinase, dGK/ DGUOK 1.0 1.8 2p13.1 n.a n.a n.a APRT adenine phosphoribosyltransferase 0.4 0.6 16q24.3 gain gain gain ADA adenosine deaminase 0.9 0.1 20q13.2 gain gain gain PPAT phosphoribosyl pyrophosphate amidotransferase 1.1 1.3 4q12 n.a n.a n.a MRP1/ABCC1 ATP-binding cassette, sub-family C (CFTR/MRP) member 1 1.5 0.7 16p13.11 n.a n.a n.a MRP2/ABCC2 ATP-binding cassette, sub-family C (CFTR/MRP) member 2 0.8 0.8 10q24.2 n.a n.a n.a
MRP3/ABCC3
ATP-binding cassette, sub-family C (CFTR/MRP) member 3 1.0 1.0 17q21.33 n.a gain n.a P-glycoprotein ATP-binding cassette, sub-family B (MDR/TAP) member 1 1.2 0.9 7q21.12 n.a n.a n.a CBS cystathionine β-synthase 0.5 0.0 21q22.3 gain gain n.a Expression levels are in relation to parental cells (MTX / parental or 7-OHMTX / parental) giving an arbitrary value of 1.0 for parental cells DNA copy number are in relation to normal reference DNA; n.a = no aberration detected Expression changes greater than 2-fold and copy number aberrations above thresholds are indicted in bold A c c e p t e d M a n u s c r i p t 
